Fibromyalgia Treatment Market Size, Share, and Trends 2025 to 2034

Fibromyalgia Treatment Market (By Treatment Type: Pharmacologic Therapies, Non-Pharmacologic Therapies, Device & Neuromodulation Therapies, Digital Therapeutics, Combination / Multimodal Care Pathways; By Pharmacologic Class: Anticonvulsants / α2δ Ligands, SNRIs, Tricyclic Antidepressants, Opioids & Weak Opioids, Analgesics / NSAIDs, NMDA Modulators, Serotonergic Modulators, Novel Small Molecules, Cannabinoids & Complementary Botanicals) - Global Industry Analysis, Size, Trends, Leading Companies, Regional Outlook, and Forecast 2025 to 2034

Last Updated : 18 Nov 2025

Revenue, 2024: USD 3.49 Bn
Forecast Year, 2034: USD 5.16 Bn
CAGR, 2025 - 2034: 3.97%

The global fibromyalgia treatment market size is calculated at USD 3.63 billion in 2025 and is predicted to increase from USD 3.78 billion in 2026 to approximately USD 5.16 billion by 2034, expanding at a CAGR of 3.97% from 2025 to 2034. The growing adoption of combination therapies, biologics, and personalized medicine approaches enhances treatment outcomes, driving the market's growth in emerging nations. The three drugs that are FDA‑approved specifically for fibromyalgia include pregabalin (Lyrica), duloxetine (Cymbalta), and milnacipran (Savella).

North America dominated the fibromyalgia treatment market with the largest market share of 54% in 2024. Asia Pacific is expected to be the fastest‑growing region in the upcoming years.

By treatment type, the pharmacologic segment captured the biggest market share of 55% in 2024. By treatment type, the digital therapeutic segment is expected to grow with the highest CAGR in the market during the studied years. By pharmacologic class, the anticonvulsants / α2δ ligands segment led the market in 2024. By pharmacologic class, the analgesics / NSAIDs segment is expected to show the fastest growth over the forecast period.

The fibromyalgia treatment market covers pharmacologic and non‑pharmacologic therapies used to manage fibromyalgia (a chronic centralized pain syndrome characterized by widespread pain, fatigue, sleep disturbance, and cognitive symptoms). The market includes approved drugs, off‑label medications, non‑drug therapies (exercise, CBT, physical therapy), neuromodulation and device‑based pain management, digital therapeutics/telehealth programs, combination care pathways, and related services (diagnosis, long‑term management, and specialty pain clinic services).

AI integration is significantly transforming the growth of the fibromyalgia treatment market by accelerating the process of drug discovery, the potential to revolutionize diagnosis, and optimizing clinical trials. AI algorithms assist in identifying potential drug candidates by effectively analyzing large datasets and predicting their efficacy. Several researchers and healthcare specialists are increasingly exploring the potential of AI to identify objective biomarkers, improve diagnostic accuracy, and obtain deeper knowledge into the underlying mechanisms of fibromyalgia. AI‑powered solutions enhance diagnostic accuracy, personalize treatment plans, and improve overall treatment outcomes.

Industry Growth Overview
The fibromyalgia treatment market is growing, driven by increasing prevalence of the health condition and a deeper understanding of its significant mechanisms. Advancement of novel drugs, the growing application of combined treatments such as medications, lifestyle changes, and non‑pharmacological therapies, and an increasing in post‑COVID‑19 fibromyalgia cases.

Global Expansion
The fibromyalgia treatment market is experiencing global expansion, as growing awareness, rising diagnoses, and the development of novel pharmaceutical and non‑pharmaceutical therapies. North America is dominated in the market due to the increasing prevalence of the condition, robust research and development spending from pharmaceutical companies.

Major investors
The major players and investors in the fibromyalgia treatment market are primarily large pharmaceutical and biopharmaceutical companies, with Pfizer Inc., Eli Lilly and Company, and AbbVie Inc., which developed and market a number of FDA‑approved drugs.

Key Trends
The rising development of innovative treatment options for fibromyalgia is expected to drive the market's growth during the forecast period.
The surging healthcare expenditure and insurance coverage for chronic pain management are anticipated to promote the growth of the fibromyalgia treatment market.
The surge in the female population will significantly fuel the expansion of the fibromyalgia treatment market in the coming years.
The increasing advancement in medical research focused on effective treatment options is expected to accelerate the market's revenue during the forecast period.
The increasing introduction of new drug classes, which may offer high efficacy and tolerability, is propelling the growth of the market during the forecast period.

Market Scope
Market Size by 2034: USD 5.16 Billion
Market Size in 2026: USD 3.78 Billion
Market Size in 2025: USD 3.63 Billion
Market Growth Rate from 2025 to 2034: CAGR of 3.97%
Dominating Region: North America
Fastest Growing Region: Asia Pacific
Base Year: 2024
Forecast Period: 2025 to 2034
Segments Covered: Treatment Type, Pharmacologic Class, and Region
Regions Covered: North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Market Dynamics
Drivers
Growing Demand for Fibromyalgia Treatment
The surge in the number of fibromyalgia cases, particularly among women, is expected to boost the growth of the fibromyalgia treatment market during the forecast period.

Restraint
Prohibitive Treatment Costs
The high cost associated with the fibromyalgia treatment is anticipated to hamper the market's growth.

Opportunity
Rising Research and Development Expenditure
The increasing research and development activities are projected to offer lucrative growth opportunities to the fibromyalgia treatment market in the coming years.

Sehmental Insights
Treatment Type Insights
In 2024, the pharmacologic segment registered its dominance.

Pharmacologic Class Insights
The anticonvulsants / α2δ ligands were dominant, with the biggest share of the global fibromyalgia treatment market in 2024.

Regional Analysis
U.S. Fibromyalgia Treatment Market Size and Growth 2025 to 2034
The U.S. fibromyalgia treatment market size is exhibited at USD 1.37 billion in 2025 and is projected to be worth around USD 1.98 billion by 2034, growing at a CAGR of 4.14% from 2025 to 2034.

The U.S. country has a well‑established healthcare infrastructure, a robust presence of key pharmaceutical companies, high per capita healthcare expenditure, a surge in the women's population, and increasing availability of effective drugs & therapies.

Asia Pacific Expansion
During 2025-2034 in the fibromyalgia treatment market, the Asia Pacific market is expanding steadily, attributed to the high incidences of fibromyalgia, extensive pharmaceutical industry, favorable reimbursement policies, expanding regulatory approval, growing demand for chronic pain management, and rapid advancement in medical research focused on effective treatment options.

India: Large‑scale Generic Drug Production
India is a worldwide leader in generic healthcare manufacturing. The loss of patent protection for key fibromyalgia drugs such as Lyrica (pregabalin) has enabled Indian manufacturers like Lupin Limited, Sun Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd.

Europe: Rising awareness and diagnosis
Europe is significantly growing the market due to rising awareness, a growing prevalence of the chronic condition, and a stronger medical care infrastructure.

UK: Increasing Aging Population
In the UK, increasing emphasis is placed on inclusive treatment plans that incorporate different strategies.

Fibromyalgia Treatment Market- Value Chain Analysis
R&D: The R&D process for fibromyalgia treatments usually follows the standard drug advancement pipeline, which includes basic research and preclinical testing.
Key Players: Pfizer Inc. and AbbVie Inc.
Clinical Trials: Key Players: Eli Lilly and Company.
Patient Services: Key Players: GlaxoSmithKline (GSK) plc and Teva Pharmaceutical Industries Ltd.

Top Vendors in the Fibromyalgia Treatment Market & Their Offerings
Pfizer – United States – Robust R&D capabilities
Eli Lilly – Indianapolis, Indiana, USA – Robust and innovative product portfolio
Teva Pharmaceutical Industries – Tel Aviv, Israel – Leadership in generic medicines
Allergan / AbbVie – North Chicago, Illinois – Robust R&D innovations
Novartis – Basel, Switzerland – Strong financial performance

Other Major Companies
Sun Pharmaceutical Industries, Astellas Pharma, Tonix Pharmaceuticals, Aptinyx, Axsome Therapeutics, Scilex, Johnson & Johnson, Medtronic, Boston Scientific, Nevro Corp., Abbott

Latest Announcements by Industry Leaders
In October 2025, AbbVie announced positive topline results from the Phase 2 ELATE trial evaluating the safety and efficacy of onabotulinumtoxinA (BOTOX) for the treatment of upper limb essential tremor.

In July 2024, the FDA granted fast‑track designation to a sublingual tablet form of the muscle relaxant cyclobenzaprine hydrochloride for the management of fibromyalgia. Tonix Pharmaceuticals reported that its patented form of the drug, Tonmya, received the designation following the results of the phase 3 RESILIENT study.

In October 2024, Lin Health, a digital platform helping people reclaim their lives from chronic pain, announced a collaboration with Mayo Clinic to improve care transition support for patients who complete the Fibromyalgia Treatment Program on Mayo Clinic's campus in Rochester, Minnesota. Following the initial few months of results, the collaboration is slated to expand to support Mayo Clinic primary care patients in Arizona.

In January 2025, Silo Pharma, Inc., a developmental‑stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, announced that the U.S. Patent and Trademark Office (USPTO) issued a notice of allowance for patent application 17/954,864 for pharmacological prophylactics against stress‑induced affective disorders in females.

Segments Covered in the Report
By Treatment Type: Pharmacologic Therapies, Non‑Pharmacologic Therapies, Device & Neuromodulation Therapies, Digital Therapeutics, Combination / Multimodal Care Pathways
By Pharmacologic Class: Anticonvulsants / Α2δ Ligands, SNRIs, Tricyclic Antidepressants, Opioids & Weak Opioids, Analgesics / NSAIDs, NMDA Modulators, Serotonergic Modulators, Novel Small Molecules, Cannabinoids & Complementary Botanicals
By Region: North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Fibromyalgia Treatment Market Size to Hit USD 5.16 Billion by 2034

The global fibromyalgia treatment market is projected to grow from USD 3.49 billion in 2024 to USD 5.16 billion by 2034, expanding at a CAGR of 3.97% from 2025 to 2034. North America dominates the market, while Asia‑Pacific is expected to be the fastest‑growing region. The market is driven by pharmacologic therapies, digital therapeutics, and AI‑driven drug discovery, with key players including Pfizer, Eli Lilly, AbbVie, Teva, and Novartis.